MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA

5 years ago

by David Miller

949 Views

Written by David Miller

ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!